1284151-33-2

Basic information

• Product Name: C₃H₄O₄*C₃₀H₃₉FN₄O₄
• Synonyms: C₃H₄O₄*C₃₀H₃₉FN₄O₄
• CAS NO: 1284151-33-2
• Molecular Weight: 642.725
• Mol File: 1284151-33-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₃H₄O₄*C₃₀H₃₉FN₄O₄(CAS DataBase Reference)
• NIST Chemistry Reference: C₃H₄O₄*C₃₀H₃₉FN₄O₄(1284151-33-2)
• EPA Substance Registry System: C₃H₄O₄*C₃₀H₃₉FN₄O₄(1284151-33-2)

Safety Data

• Hazardous Substances Data: 1284151-33-2(Hazardous Substances Data)

Upstream product

• 874336-42-2 (R)-2-((R)-2-((S)-2-(((R)-2-(2-(3-aminopropyl)phenoxy)propyl)-amino)-2-cyclopropyl-N-methylacetamido)propanamido)-3-(4-fluorophenyl)propanoic acid 
• 1284151-25-2 C₄₅H₅₃FN₄O₇ 
• 874336-39-7 C₂₀H₂₃FN₂O₃*ClH 
• 874336-45-5 C₂₅H₃₂N₂O₅*ClH 
• 842131-33-3 ulimorelin 
• 141-82-2 malonic acid 

Relevant articles and documents

SALTS, SOLVATES, AND PHARMACEUTICAL COMPOSITIONS OF MACROCYCLIC GHRELIN RECEPTOR AGONISTS AND METHODS OF USING THE SAME

The present invention provides novel salts and solvates of macrocyclic compounds that bind to and/or are functional agonists of the ghrelin (growth hormone secretagogue) receptor. The invention also relates to polymorphs of these salts and solvates, pharmaceutical compositions containing these salts or solvates, and methods of using the pharmaceutical compositions. These pharmaceutical compositions are useful as therapeutics for a range of disease indications, in particular, for treatment and prevention of gastrointestinal disorders including, but not limited to, postoperative ileus, gastroparesis, including diabetic and postsurgical gastroparesis, opioid bowel dysfunction, chronic intestinal pseudo-obstruction, short bowel syndrome, functional gastrointestinal disorders and gastrointestinal dysmotility, such as that occurring in conjunction with other disease states, in critical care situations or as a result of treatment with pharmaceutical agents. Additionally, the pharmaceutical compositions have application to the treatment and prevention of metabolic and/or endocrine disorders, cardiovascular disorders, central nervous system disorders, bone disorders, inflammatory disorders, hyperproliferative disorders, disorders characterized by apoptosis and genetic disorders.